Domino Data Lab partners with Appsilon to deliver a governed, open‑source AI pipeline for life‑science firms navigating strict regulatory demands.
Domino Data Lab, a provider of an end‑to‑end AI platform for highly regulated enterprises, announced a strategic collaboration with Appsilon, a specialist in open‑source software and AI solutions for the pharmaceutical and life‑science sectors. The partnership, revealed on June 25 2026, aims to bridge the gap that many life‑science organizations face when moving AI models from experimental notebooks into production‑grade environments.
From Experimentation to Validated Production
Life‑science companies often experiment with R and Python in ad‑hoc settings, only to encounter roadblocks when attempting to scale those models under regulatory scrutiny. Domino’s Domino platform, which offers governance, scaling, and monitoring capabilities, now integrates Appsilon’s deep implementation know‑how—particularly around the Scientific Computing Environment (SCE) and migrations from SAS to open‑source stacks. The combined offering promises a smoother transition from prototype to a compliant, auditable deployment.
“Most life‑science organizations have data scientists who are ready to build. What’s missing is a validated environment that lets them get work into production,” said Ricky Mann, Chief Solutions Officer at Domino Data Lab. “Appsilon has spent years solving that implementation problem for some of the largest pharmaceutical companies in the world. This partnership means Domino customers can tap that expertise directly inside the platform, with the governance regulators require.”
“The bottleneck is infrastructure that can’t keep pace with what teams are trying to build. What they need is a governed path to production that holds up in an audit. Domino is the right platform to deliver that at scale, and this partnership means Appsilon’s implementation expertise is now part of what Domino customers can access.” — Olga Mierzwa‑Sulima, CEO of Appsilon
Technical Highlights
- R and Python Expertise: Appsilon contributes proven practices for developing and validating code in the languages most data scientists in pharma use today.
- SCE Deployment: The joint solution includes support for the Scientific Computing Environment, a common compute framework in life‑science research.
- SAS‑to‑Open‑Source Migration: Companies still reliant on legacy SAS pipelines can transition to modern, open‑source toolchains without losing analytical fidelity.
- Governance Built In: All of the above is delivered through Domino’s platform, which already embeds audit trails, role‑based access controls, and model monitoring.
Extending the Platform with Partner‑Built Tools
Domino’s extensions framework, which allows third‑party developers to embed utilities directly into the AI workspace, now hosts Appsilon’s Axon.R. The tool functions as an R‑package validation suite created in collaboration with the Pharmaverse Council and leverages the risk‑based methodology of the R Validation Hub. By embedding Axon.R, life‑science teams can run compliance‑ready validation checks without leaving the Domino environment, thereby reducing friction between development and regulatory review.
Why This Matters for Enterprise AI
The collaboration underscores a broader industry shift: regulated sectors are demanding more robust MLOps solutions that can satisfy both rapid innovation cycles and stringent compliance requirements. By marrying open‑source flexibility with enterprise‑grade governance, Domino and Appsilon are positioning themselves as a one‑stop shop for pharma firms looking to adopt AI at scale while staying audit‑ready.
For enterprises, the practical impact includes:
- Reduced Time‑to‑Value: Faster movement from model prototyping to production reduces costly delays.
- Lower Compliance Risk: Integrated validation tools and built‑in governance help meet FDA, EMA, and other regulatory expectations.
- Cost Efficiency: Leveraging open‑source ecosystems cuts licensing expenses compared with proprietary stacks.
- Scalable Architecture: Domino’s cloud‑agnostic platform supports both on‑premises and hybrid deployments, a key consideration for data‑sensitive pharma workloads.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
